Rebecca Phillips, NP
Payments from drug & device makers
Across 42 payments — averaging $190.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$7K
- Daiichi Sankyo Inc.$259
- Deciphera Pharmaceuticals Inc.$131
- Takeda Pharmaceuticals U.S.A., Inc.$122
- Eisai Inc.$104
- Incyte Corporation$100
- plus $143 from 4 others
What the payments were for
- Speaking & faculty fees$5,32066%
- Travel & lodging$1,07413%
- Food & beverage$1,61620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 24 | $7,152 |
| Daiichi Sankyo Inc. | 7 | $259 |
| Deciphera Pharmaceuticals Inc. | 1 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $122 |
| Eisai Inc. | 3 | $104 |
| Incyte Corporation | 1 | $100 |
| Gilead | 1 | $75 |
| Novo Nordisk | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,010 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $19,800 |
| Oxycodone Hcl | 76 | $1,532 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $1,044 |
| Letrozole | 51 | $1,038 |
| Metronidazole | 11 | $683 |
| Mirtazapine | 27 | $511 |
| Gabapentin | 22 | $502 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $454 |
| Potassium Chloride | 22 | $445 |
| Ondansetron Hcl | 22 | $374 |
| Levothyroxine Sodium | 23 | $334 |
| Cefdinir | 19 | $306 |
| Doxycycline Hyclate | 21 | $284 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $248 |
| Tamoxifen Citrate | 13 | $247 |
Paid to pharmacies, not to this prescriber.
Other family in Cary
- Amanda KellyCary$94K
- Daria LewisCary$66K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.